Position with BioTime|
Officer and Director|
Financial Officer and Senior Vice President, Finance|
E. Patton, Ph.D., J.D.
Roberts, Chief Financial Officer and Senior Vice President, Finance. Ms.
Roberts was appointed as BioTime’s Chief Financial Officer and Senior Vice President, Finance effective January 7, 2019.
Ms. Roberts previously served as Chief Financial Officer of REVA Medical, Inc. from August 2017 until December 2018. From March
2011 through August 2017, Ms. Roberts served in various roles at Mast Therapeutics, Inc., including Chief Financial Officer from
January 2013 to April 2017 and Senior Vice President, Finance, from March 2011 to January 2013. Previously, Ms. Roberts held senior
positions at Alphatec Holdings, Inc., Artes Medical, Inc., Stratagene California and Pfizer Inc. Ms. Roberts is a certified public
accountant with the State of California and received her B.S. in Business Administration from the University of Arizona and her
M.B.A. from the University of San Diego.
E. Patton, Ph.D., J.D., General Counsel and Corporate Secretary. Dr. Patton was appointed as BioTime’s General Counsel
during February 2017. Dr. Patton brings 20 years of experience creating portfolio value at publicly-traded biotechnology
and pharmaceutical companies. Dr. Patton was formerly the General Counsel and Commercial Compliance Officer at BioDelivery Sciences
from 2015 - 2017, a publicly-traded specialty pharmaceutical company. Prior to BioDelivery Sciences, she held various senior management
positions, including leading Intellectual Property (“IP”) and Licensing at Salix Pharmaceuticals from
2007 - 2015, a global pharmaceutical company that was acquired for $11.2 Billion in 2015. Prior to joining Salix, Dr. Patton was
in private practice from 1999-2007 at a large international law firm known for its IP and corporate securities practices and at
a boutique IP firm. Her practice focused on counseling clients on IP-related matters as well as licensing transactions for biotechnology
and pharmaceutical companies at varying stages of product development. Dr. Patton earned a Juris Doctor (J.D.) degree from the
Boston University School of Law and a Ph.D. in Biochemistry, Cell and Developmental Biology from Emory University.
executive officers are elected by, and serve at the discretion of, the board of directors. There are no family relationships among
any of the currently expected directors and current executive officers of BioTime.
the eight current members of the BioTime Board, six have been determined to be “independent” in accordance with Section
803(A) of the NYSE American Company Guide. These six current BioTime directors are Deborah Andrews, Neal C. Bradsher, Stephen
C. Farrell, Michael H. Mulroy, Cavan Redmond, and Angus C. Russell. Brian M. Culley, a current member of BioTime’s board
and BioTime’s Chief Executive Officer, is not independent within the meaning of applicable NYSE American Rules. Alfred D.
Kingsley does not qualify as “independent” because he receives compensation for serving in an executive role as Chairman
of certain of BioTime’s subsidiaries. Prior to the appointment of Don M. Bailey to the BioTime Board, the BioTime Board
will determine whether these individuals are independent (as to BioTime) within the meaning of applicable NYSE American Rules,
and whether Mr. Bailey is expected to serve as members of BioTime’s audit committee immediately following the completion
of the merger meet the additional independence requirements set forth in Rule 10A-3 under the Securities Exchange Act of 1934,